معرفی
Jon Merlin is a Research Fellow in Drug Discovery Biology at Monash University, Australia. He is actively engaged in pharmacological research focusing on G protein-coupled receptors (GPCRs), metabolic regulation, and drug development for chronic diseases such as diabetes and heart failure. His work spans molecular pharmacology, receptor signaling dynamics, and translational drug discovery.
His research interests include Molecular Pharmacology, G Protein-Coupled Receptors, Drug Discovery, Metabolic Disease, Biased Agonism, and Inflammation Resolution. These areas are central to understanding how receptor-ligand interactions can be optimized for therapeutic benefit.
The recent publication trends indicate a strong focus on receptor kinetics, metabolic homeostasis, and cardiovascular pharmacology. His studies often involve in vitro and in vivo models to dissect signaling pathways of GPCRs relevant to diabetes (e.g., GLP-1R), obesity (e.g., β3-adrenoceptors), and inflammation (e.g., proresolving receptors).
Jon Merlin has collaborated extensively with leading researchers at Monash University, including Professors Christopoulos, Sexton, Summers, and Langmead. He was a visiting researcher at Stockholm University from March to June 2014, reflecting international academic engagement.
Scientific Contributions:
- Investigated ligand-receptor binding kinetics of GLP-1R for diabetes therapeutics.
- Characterized proresolving GPCRs for anti-inflammatory drug development.
- Explored GPR21 deletion effects on glucose metabolism and inflammation.
- Evaluated adenosine receptor biased agonists for heart failure treatment.
- Confirmed β3-adrenoceptor mediation of mirabegron’s metabolic effects.
While no formal advising or grant information is provided, his consistent publication record and collaborative network suggest active involvement in funded research projects and mentorship within the Drug Discovery Biology group. His work contributes to UN Sustainable Development Goals related to good health and well-being.
